{
  "id": "antiemetics_pharmacology_001",
  "updatedAt": "2026-02-18T00:00:00Z",

  "domain": "pharmacology",
  "topicTagIds": ["antiemetics", "pharmacology", "ponv"],
  "caseId": null,
  "slotType": "any",
  "caseOrder": 0,

  "demographics": {
    "patientAgeGroup": "adult",
    "patientGender": "female"
  },

  "stem": "Dr. {{candidate_name}}, tell me about antiemetic drugs used in anaesthesia.",

  "prompts": [
    {
      "tier": "recall",
      "text": "What are the main classes of antiemetic drugs and give examples?",
      "expectedKeyFacts": [
        "5-HT3 antagonists: ondansetron, granisetron",
        "Dopamine (D2) antagonists: metoclopramide, prochlorperazine, droperidol",
        "Antihistamines (H1): cyclizine",
        "Anticholinergics: hyoscine",
        "NK1 antagonists: aprepitant",
        "Corticosteroids: dexamethasone",
        "Propofol has antiemetic properties"
      ],
      "timeBudgetSec": 60
    },
    {
      "tier": "mechanism",
      "text": "Explain how ondansetron works and its side effects.",
      "expectedKeyFacts": [
        "Selective 5-HT3 (serotonin) receptor antagonist",
        "Blocks receptors in chemoreceptor trigger zone and GI tract",
        "Dose: 4-8 mg IV",
        "Effective for PONV prevention and treatment",
        "Side effects: headache, constipation, dizziness",
        "QT prolongation — caution in cardiac patients",
        "Well tolerated overall",
        "More effective when given at end of surgery than at induction"
      ],
      "timeBudgetSec": 90
    },
    {
      "tier": "application",
      "text": "How would you assess a patient's risk of PONV and plan antiemetic prophylaxis?",
      "expectedKeyFacts": [
        "Apfel score: female gender, non-smoker, history of PONV/motion sickness, post-op opioids",
        "Each factor = 1 point; 0-1 = low risk, 2 = moderate, 3-4 = high risk",
        "High-risk surgery: laparoscopy, ENT, gynaecological, strabismus surgery",
        "Prophylaxis: multimodal approach if ≥2 risk factors",
        "Combine agents from different classes for additive effect",
        "TIVA with propofol reduces baseline risk",
        "Adequate hydration, minimize opioids, avoid N₂O",
        "Example: dexamethasone 4-8 mg + ondansetron 4 mg"
      ],
      "timeBudgetSec": 90
    },
    {
      "tier": "synthesis",
      "text": "A patient develops severe PONV in recovery despite receiving ondansetron intraoperatively. What would you give?",
      "expectedKeyFacts": [
        "Use antiemetic from different class",
        "Cyclizine 50 mg IV or IM",
        "Prochlorperazine 12.5 mg IM (avoid IV — hypotension risk)",
        "Dexamethasone 4-8 mg IV if not already given",
        "Metoclopramide 10 mg IV",
        "Consider acupressure (P6 stimulation)",
        "Avoid repeat ondansetron within 4-6 hours",
        "Ensure adequate hydration and minimize opioid dose",
        "Consider switching to non-opioid analgesia"
      ],
      "timeBudgetSec": 90
    },
    {
      "tier": "evaluation",
      "text": "Why is dexamethasone commonly used for PONV prophylaxis despite being a steroid?",
      "expectedKeyFacts": [
        "Highly effective for PONV prevention (mechanism not fully understood)",
        "Works via anti-inflammatory and central antiemetic effects",
        "Single dose 4-8 mg has minimal side effects",
        "Long duration of action (~24 hours)",
        "Most effective when given at induction",
        "Synergistic with other antiemetics",
        "Low cost and widely available",
        "Concerns: hyperglycaemia (minimal with single dose), delayed wound healing (not clinically significant)",
        "Relative contraindications: active peptic ulcer, poorly controlled diabetes"
      ],
      "timeBudgetSec": 60
    }
  ],

  "rescuePrompt": "Perhaps you could tell me about the Apfel score — what are the risk factors for PONV?",

  "keyFacts": [
    "5-HT3 antagonists (ondansetron), D2 antagonists (metoclopramide), H1 antagonists (cyclizine)",
    "Ondansetron 4-8 mg IV, blocks 5-HT3 receptors",
    "Apfel score: female, non-smoker, PONV history, opioids",
    "Multimodal prophylaxis for high-risk patients",
    "Dexamethasone 4-8 mg at induction",
    "Avoid N₂O, use TIVA, minimize opioids",
    "Ondansetron QT prolongation",
    "Cyclizine 50 mg for rescue",
    "Combine different classes for additive effect",
    "P6 acupressure can help"
  ],

  "scoringGuidance": {
    "pass": "Lists main antiemetic classes with examples, explains ondansetron mechanism and side effects, knows Apfel score and risk stratification, describes multimodal approach, appropriate rescue therapy using different class; stronger candidates discuss optimal timing and dexamethasone rationale",
    "borderline": "Knows some antiemetics but classification unclear, mentions ondansetron but mechanism vague, aware of PONV risk but Apfel score incomplete, rescue therapy non-systematic",
    "fail": "Cannot classify antiemetics, does not understand mechanisms, unaware of risk assessment or prophylaxis strategies, inappropriate rescue therapy"
  },

  "author": "SimViva Team",
  "provenance": {
    "generatedBy": "Claude (Anthropic)",
    "generatedAt": "2026-02-18T22:10:00Z",
    "promptVersion": "v1.0.0",
    "sourceMaterial": ["PONV_Consensus_Guidelines_2020", "BJA_Antiemetics_2019"],
    "validation": {
      "reviewedBy": "",
      "reviewedAt": "",
      "status": "pending_review",
      "notes": "Awaiting clinical reviewer sign-off."
    }
  },
  "furtherReading": [
    "https://doi.org/10.1213/ANE.0000000000004833"
  ],
  "isActive": true
}
